Hasten Ventures, through its investment vehicle Hasten Kapital, participates in Biotech start-up FASTBASE Solutions.
The company was founded in 2016 by international cancer cell biology scientists from the Francis Crick Institute (UK), the Centre for Therapeutic Innovation at the University of Bath (UK), the Institute of Molecular and Cellular Biology at the UMH of Elche (Spain) and the Biofisika Institute at the University of the Basque Country UPV/EHU.
FASTBASE has developed AFRET: a proprietary high-resolution “companion diagnostics” technology platform capable of quantifying the activation and interaction states of proteins in histopathology. First milestone is to launch an assay to quantify the population of PD-1/PD-L1 interacting ligand-receptor pairs formed in cancer biopsies, as a predictive marker for potential patient’s response to immunotherapy.